Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
The pheochromocytomas are an important cause of secondary hypertension. Although pheochromocytoma susceptibility may be associated with germline mutations in the tumor-suppressor genes VHL and NF1 and in the proto-oncogene RET, the genetic basis for most cases of nonsyndromic familial pheochromocytoma is unknown. Recently, pheochromocytoma susceptibility has been associated with germline SDHD mutations. Germline SDHD mutations were originally described in hereditary paraganglioma, a dominantly inherited disorder characterized by vascular tumors in the head and the neck, most frequently at the carotid bifurcation. The gene products of two components of succinate dehydrogenase, SDHC and SDHD, anchor the gene products of two other components, SDHA and SDHB, which form the catalytic core, to the inner-mitochondrial membrane. Although mutations in SDHC and in SDHD may cause hereditary paraganglioma, germline SDHA mutations are associated with juvenile encephalopathy, and the phenotypic consequences of SDHB mutations have not been defined. To investigate the genetic causes of pheochromocytoma, we analyzed SDHB and SDHC, in familial and in sporadic cases. Inactivating SDHB mutations were detected in two of the five kindreds with familial pheochromocytoma, two of the three kindreds with pheochromocytoma and paraganglioma susceptibility, and 1 of the 24 cases of sporadic pheochromocytoma. These findings extend the link between mitochondrial dysfunction and tumorigenesis and suggest that germline SDHB mutations are an important cause of pheochromocytoma susceptibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a biallelic loss of succinate dehydrogenase (SDH), an alteration found in familial paragangliomas and pheochromocytomas, as well as in a subset of sporadic gastrointestinal stromal tumors, creates a build-up of succinate (Astuti et al., 2001; Janeway et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Astuti et al., 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The results of a clinical study further confirmed this observation by showing that patients with nonmetastatic lung cancer harbored loss-of-function mutations in SDH5128.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
Experimental — accuracy not yet measuredIn the citing paper
“In cancer cells, mutations in succinate dehydrogenase subunit B (SDHB) cause susceptibility to familial pheochromocytoma99 and familial paraganglioma100 as well as gastrointestinal stromal tumors101.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [99]
In the citing paper
“In addition to the tumorigenic effects of succinate accumulation, SDH5 mutation is the key driver supporting the acquisition of epithelial–mesenchymal transition (EMT) characteristics.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 3×
“…the iron-sulfur–protein subunit) and in both SDHC and SDHD (i.e., the genes for the integral membrane–protein subunits) are associated with neoplasia (Baysal et al. 2000; Niemann and Muller 2000; present study), autosomal recessive homozygous SDHA (i.e., the gene for the flavoprotein subunit)…”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundCockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050 · cited 1×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 4×
“…herein: PGL1 (MIM 168000), which results from SDHD mutations at 11q23; PGL2 (MIM 601650), which maps to 11q13, although the causative gene has not been identified (Mariman et al. 1995); and PGL3 (MIM 605373), which results from SDHC mutations at 1q21 (Baysal et al. 2000; Niemann and Muller 2000).”
BackgroundInfluentialBourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730 · cited 2×
“SDHA mutations are associated with juvenile encephalopathy (Bourgeron et al. 1995), and the phenotypic consequences of SDHB mutations have not been defined.”
BackgroundHoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382 · cited 1×
“Interestingly, germline VHL mutations that predispose patients to pheochromocytoma do not impair HIF-1a ubiquitylation (Clifford et al. 2001; Hoffman et al. 2001).”
BackgroundClifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Gimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Self-citation
Cited by
Items 201–300 of 999
Metabolic Plasticity of Tumor Cell Mitochondria
Cannino, G., Ciscato, F., Masgras, I., Sànchez‐Martìn, C., & Rasola, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00333 · Cited by 103
68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours
Naji, M., Zhao, C., Welsh, S. J., Meades, R., Win, Z., Ferrarese, A., Tan, T., Rubello, D., & AL-NAHHAS, A. M. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0396-8 · Cited by 98
Glunde, K., Jiang, L., Moestue, S. A., & Gribbestad, I. S. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1751 · Cited by 105
The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 103
Genetic screening for pheochromocytoma: should SDHC gene analysis be included?: Figure 1
Mannelli, M., Ercolino, T., Giachè, V, Simi, L., Cirami, C., & Parenti, G. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.051045 · Cited by 95
Genetic insights into familial cancers – update and recent discoveries
Marsh, D. J., & Zori, R. T. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00023-x · Cited by 114
Douwes Dekker, P., Hogendoorn, P., Kuipers‐Dijkshoorn, N., Prins, F., van Duinen, S., Taschner, P., van der Mey, A., & Cornelisse, C. (2003) · The Journal of Pathology · doi:10.1002/path.1461 · Cited by 94
“Sporadic cases in which SDHD mutation analysis proved to be negative were subsequently analysed for the presence of SDHB mutations as described previously [16,17].”
Multiple Endocrine Neoplasia Syndromes
Callender, G. G., Rich, T. A., & Perrier, N. D. (2008) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.05.001 · Cited by 103
The genetics of paragangliomas: a review
Martin, T., Irving, R. M., & Maher, E. R. (2007) · Clinical Otolaryngology · doi:10.1111/j.1365-2273.2007.01378.x · Cited by 103
Self-citationBiochemical Assays for Mitochondrial Activity: Assays of TCA Cycle Enzymes and PDHc
Saada, A., & Elpeleg, O. N. (2007) · Methods in cell biology · doi:10.1016/s0091-679x(06)80010-5 · Cited by 103
Aerobic glycolysis: a novel target in kidney cancer
Shuch, B. M., Linehan, W. M., & Srinivasan, R. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.57 · Cited by 101
A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology
Acker, T., & Plate, K. H. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0355-1 · Cited by 78
“It was subsequently shown that the HIF system is constitutively activated in RCC lacking a functional pVHL. Loss of pVHL function leads to stabilization of HIF-α subunits already under normoxic conditions, while reintroduction of a functional VHL gene restored HIF regulation [33, 59].”
BackgroundInfluentialMannelli, M., Lenders, J. W. M., Pacák, K., Parenti, G., & Eisenhofer, G. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.008 · Cited by 108
Pheochromocytoma – update on disease management
Därr, R., Lenders, J. W. M., Hofbauer, L. C., Naumann, B., Bornstein, S. R., & Eisenhofer, G. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812437356 · Cited by 103
“Thus, in patients with these catecholamine biochemical profiles mutations of SDHB and SDHD genes should be considered.”
BackgroundInfluentialRecent developments in the treatment of renal cell carcinoma
Dutcher, J. P. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213505672 · Cited by 97
“Another metabolic enzyme mutation of succinate dehydrogenase B was initially reported in familial pheochromocytoma and familial paraganglioma [Astuti et al. 2001].”
BackgroundXekouki, P., & Stratakis, C. A. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0118 · Cited by 100
“2000, Astuti et al .”
McWhinney, S. R., Pilarski, R. T., Forrester, S. R., Schneider, M. C., Sarquis, M. M., Dias, E. P., & Eng, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0769 · Cited by 89
Self-citationLuchetti, A., Walsh, D. M., Rodger, F., Clark, G. R., Martin, T., Irving, R. M., Sanna, M., Yao, M., Robledo, M., Neumann, H. P. H., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/138573 · Cited by 100
Self-citationRemacha, L., Comino‐Méndez, I., Richter, S., Contreras, L., Currás-Freixes, M., Pita, G., Letón, R., Galarreta, A., Torres‐Pérez, R., Honrado, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2250 · Cited by 105
“Up to 40% of individuals with PCC and/or PGL have a hereditary background due to germline mutations affecting one of thirteen susceptibility genes (2-13).”
BackgroundOncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory
Collins, R. R. J., Patel, K., Putnam, W. C., Kapur, P., & Rakheja, D. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.267666 · Cited by 90
Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma
Favier, J., Igaz, P., Burnichon, N., Amar, L., Libé, R., Badoual, C., Tissier, F., Bertherat, J. Y., Plouin, P., Jeunemaître, X., et al. (2011) · Endocrine Pathology · doi:10.1007/s12022-011-9189-0 · Cited by 95
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors
Liu, T., Brown, T. C., Juhlin, C. C., Stenman, A., Wang, N., Bäckdahl, M., Healy, J. M., Prasad, M. L., Korah, R. M., Carling, T., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0016 · Cited by 101
“Relationship between C228T and molecular phenotypes Mutation of the succinate dehydrogenase B gene (SDHB) is a frequent genetic event in PGL, especially in malignant PGL (Astuti et al. 2001, Gimenez-Roqueplo et al. 2003).”
BackgroundPseudohypoxic Pathways in Renal Cell Carcinoma
Bratslavsky, G., Sudarshan, S., Neckers, L., & Linehan, W. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2510 · Cited by 89
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 93
Hereditary Paraganglioma/Pheochromocytoma and Inherited Succinate Dehydrogenase Deficiency
Favier, J., Brière, J.-J., Strompf, L., Amar, L., Filali, M., Jeunemaitre, X., Rustin, P., & Gimenez-Roqueplo, A.-P. (2005) · Hormone Research in Paediatrics · doi:10.1159/000084685 · Cited by 88
Cytopathies involving mitochondrial complex II
Ackrell, B. A. C. (2002) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(02)00012-2 · Cited by 86
Genetics of hereditary head and neck paragangliomas
Boedeker, C. C., Hensen, E. F., Neumann, H. P. H., Maier, W., van Nederveen, F. H., Suarez, C. M., Kunst, H. P. M., Rodrigo, J. P., Takes, R. P., Pellitteri, P. K., et al. (2013) · Head & Neck · doi:10.1002/hed.23436 · Cited by 97
“SDHB mutations follow an autosomal dominant trait of inheritance.(20) Tumor penetrance is somewhat lower than that seen in SDHD mutation carriers.”
BackgroundModern Nuclear Imaging for Paragangliomas: Beyond SPECT
Taïeb, D., Neumann, H. P. H., Rubello, D., AL-NAHHAS, A. M., Guillet, B. A., & Hindié, E. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098152 · Cited by 90
“Consequently, paraganglioma types 3 and 4 have been described as associated with germline mutations of the genes SDHC and SDHB, respectively (7,8).”
BackgroundMarelli‐Berg, F. M., Fu, H., & Mauro, C. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03583.x · Cited by 93
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 86
Wong, L.-J. C., Lueth, M., Li, X.-N., Lau, C. C., & Vogel, H. S. (2003) · PubMed · Cited by 101
Clinical and molecular progress in hereditary paraganglioma: Figure 1
Baysal, B. E. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.058560 · Cited by 86
Nannini, M., Biasco, G., Astolfi, A., & Pantaleo, M. A. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101695 · Cited by 88
Management of head and neck paragangliomas: Review of 120 patients
Papaspyrou, K., Mann, W. J., & Amedee, R. G. (2008) · Head & Neck · doi:10.1002/hed.20967 · Cited by 86
Respiratory chain complex II as general sensor for apoptosis
Grimm, S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.09.009 · Cited by 82
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel
Wojtovich, A. P., Smith, C. O., Haynes, C. M., Nehrke, K. W., & Brookes, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.007 · Cited by 83
“or nonsense mutations typically produce slow growing or benign (SDHC [8] and SDHD [9]) or highly aggressive (SDHB [10]) tumors of the carotid body, classified as hereditary paragangliomas or pheochromocytomas.”
BackgroundEisenhofer, G., Klink, B., Richter, S., Lenders, J. W. M., & Robledo, M. (2017) · Europe PMC (PubMed Central) · Cited by 110
Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma
Hensen, E. F., & Bayley, J. (2010) · Familial Cancer · doi:10.1007/s10689-010-9402-1 · Cited by 90
“gangliomas [2] led to a recognition that paragangliomas and pheochromocytomas share not only similar cellular origins, but can also have a comparable genetic basis.”
BackgroundGenetics and molecular pathogenesis of pheochromocytoma and paraganglioma
Galan, S., & Kann, P. H. (2013) · Clinical Endocrinology · doi:10.1111/cen.12071 · Cited by 93
Jackson, C. B., Nuoffer, J., Hahn, D., Prokisch, H., Haberberger, B., Gautschi, M., Häberli, A., Gallati, S., & Schaller, A. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101932 · Cited by 94
Etiopathogenesis and clinical presentation of carotid body tumors
Baysal, B. E., & Myers, E. N. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10200 · Cited by 83
“…family history, hereditary paraganglioma (PGL) is responsible for the tumors described in any component of the paraganglia (including pheochromocytomas [Gimm et al., 2000; Astuti et al., 2001b] and extraadrenal paragangliomas), which may be located anywhere from the skull base to the pelvic floor.”
BackgroundInfluentialVan Coster, R., Seneca, S., Smet, J., Van Hecke, R., Gerlo, E., Devreese, B., Van Beeumen, J., Leroy, J. G., De Meirleir, L., & Lissens, W. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.10202 · Cited by 83
“Mutations in the Ip subunit gene (SDHB) cause susceptibility to familial pheochromocytoma and to familial paraganglioma [Astuti et al., 2001].”
BackgroundGenetic heterogeneity among uterine leiomyomata: insights into malignant progression
Hodge, J. C., & Morton, C. C. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm043 · Cited by 83
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research
Ooi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.016 · Cited by 90
Srirangalingam, U., Walker, L., Khoo, B. C. E., MacDonald, F., Gardner, D. S.-L., Wilkin, T. J., Skelly, R. H., George, E., Spooner, D. A., Monson, J. P., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03274.x · Cited by 93
Self-citationEmerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
Ilanchezhian, M., Jha, A., Pacák, K., & Rivero, J. D. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00787-z · Cited by 87
Fishbein, L. M., Orlowski, R. Z., & Cohen, D. L. (2013) · Journal of Clinical Hypertension · doi:10.1111/jch.12084 · Cited by 88
The genomic landscape of phaeochromocytoma
Flynn, A., Benn, D. E., Clifton-Bligh, R. J., Robinson, B. G., Trainer, A. H., James, P. A., Hogg, A., Waldeck, K., George, J., Li, J., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4503 · Cited by 89
Co-regulation of mitochondrial respiration by proline dehydrogenase/oxidase and succinate
Hancock, C. N., Liu, W., Alvord, W. G., & Phang, J. M. (2015) · Amino Acids · doi:10.1007/s00726-015-2134-7 · Cited by 93
“Mutations in SDHB, SDHC, and SDHD have been found in hereditary paraganglioma (Baysal et al. 2000; Niemann and Muller 2000; Astuti et al. 2001), gastrointestinal stromal tumors (GISTs) (Pasini et al.”
BackgroundShao, Y., Ye, G., Ren, S., Piao, H., Zhao, X., Lu, X., Wang, F., Ma, W., Li, J. X., Yin, P., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31313 · Cited by 89
The management of head-and-neck paragangliomas
Capatina, C. A.-M., Ntali, G., Karavitaki, N., & Grossman, A. B. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0223 · Cited by 79
“In the PGL-1 syndrome, genomic imprinting has consistently been described; the maternally derived allele is imprinted, so this means that only mutations inherited from the father are pathogenic (Niemann et al. 1999, Baysal et al. 2000, Astuti et al. 2001, GimenezRoqueplo et al. 2012).”
BackgroundBadenhop, R. F., Jansen, J. C., Fagan, P. A., Lord, R. S. A., Wang, Z. G., Foster, W. J., & Schofield, P. R. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.011551 · Cited by 86
Paragangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing
Martins, R., & Bugalho, M. J. (2014) · International Journal of Endocrinology · doi:10.1155/2014/794187 · Cited by 90
Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriers
Eijkelenkamp, K., Osinga, T. E., Links, T. P., & van der Horst‐Schrivers, A. N. A. (2019) · Clinical Genetics · doi:10.1111/cge.13553 · Cited by 103
“SDHx-associated tumors harbor germline and somatic mutations, consistent with Knudson's second-hit hypothesis.(12) This hypothesis states that the combination of an inactivating germline mutation as a first hit, and”
BackgroundMalignant Paragangliomas Associated with Mutations in the Succinate Dehydrogenase D Gene
Havekes, B., Corssmit, E. P. M., Jansen, J. C., van der Mey, A. G. L., Vriends, A. H. J. T., & Romijn, J. A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1993 · Cited by 81
An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma
Baysal, B. E., Willett-Brozick, J. E., Filho, P. A. A., Lawrence, E. C., Myers, E. N., & Ferrell, R. E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.019224 · Cited by 78
“4 14 17 We reasoned that either a mutation in a new hereditary paraganglioma gene or an unconventional mutation in the known hereditary paraganglioma genes was responsible for the disease.”
BackgroundHead and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients
Piccini, V., Rapizzi, E., Bacca, A., Trapani, G. D., Pulli, R., Giaché, V., Zampetti, B., Cordisco, E. L., Canu, L., Corsini, E., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0369 · Cited by 82
“2000); SDHB , located on 1p36 (Astuti et al .”
BackgroundMethodDisorders of mitochondrial function
Debray, F., Lambert, M. A., & Mitchell, G. A. (2008) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328306ebb6 · Cited by 98
Lendvai, N., Pawlosky, R., Bullova, P., Eisenhofer, G., Patocs, A., Veech, R. L., & Pacak, K. (2014) · Endocrinology · doi:10.1210/en.2013-1549 · Cited by 76
Yeast Models of Human Mitochondrial Diseases
Barrientos, A. (2003) · IUBMB Life · doi:10.1002/tbmb.718540876 · Cited by 83
Alterations of oxidative phosphorylation complexes in astrocytomas
Feichtinger, R. G., Weis, S., Mayr, J. A., Zimmermann, F., Geilberger, R., Sperl, W., & Kofler, B. (2014) · Glia · doi:10.1002/glia.22621 · Cited by 82
“…and paragangliomas, which frequently exhibit mutations in genes encoding different subunits of succinate dehydrogenase (SDH; complex II), indicating that SDH subunits act as tumor suppressors in neuroendocrine tissues (Astuti et al., 2001; Brauch et al., 1997; Favier et al., 2009).”
BackgroundJiang, X., Li, L., Ying, Z., Pan, C., Huang, S., Li, L., Dai, M., Yan, B., Li, M., Jiang, H., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.016 · Cited by 79
“Mutations in the SDHB, SDHC, and SDHD genes have been reported to cause instances of rare cancers such as familial pheochromocytoma and familial paraganglioma (Astuti et al., 2001).”
BackgroundMolecular characterisation of a common SDHB deletion in paraganglioma patients
Cascón, A., Landa, I., López-Jiménez, E. A., Díez-Hernández, A., Buchta, M., Montero‐Conde, C., Leskelä, S., Leandro-Garcia, L. J., Letón, R., Rodríguez‐Antona, C., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.054965 · Cited by 82
Self-citationThe Approach to the Patient with Paraganglioma
Neumann, H. P. H., & Eng, C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0496 · Cited by 79
Self-citationInter‐connection between mitochondria and HIFs
Tormos, K. V., & Chandel, N. S. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01031.x · Cited by 74
Shuch, B. M., Singer, E. A., & Bratslavsky, G. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.01.006 · Cited by 78
Current assessment and management of glomus tumors
Semaan, M. T., & Megerian, C. A. (2008) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0b013e32830c4595 · Cited by 84
Pheochromocytoma and Paraganglioma
Kantorovich, V., & Pacák, K. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)82015-1 · Cited by 95
Niemann, S., Müller, U., Engelhardt, D., & Lohse, P. (2003) · Human Genetics · doi:10.1007/s00439-003-0938-0 · Cited by 82
“These genes are SDHB (PGL4) located on chromosome 1p (Astuti et al. 2001), SDHC (PGL3) on chromosome 1q (Niemann and Müller 2000), and SDHD (PGL1) on chromosome 11q (Baysal et al. 2000), and encode components of mito- chondrial complex II (succinate-ubiquinone oxidoreductase).”
InfluentialGross SDHB deletions in patients with paraganglioma detected by multiplex PCR: A possible hot spot?
Cascón, A., Montero‐Conde, C., Ruiz‐Llorente, S., Mercadillo, F., Letón, R., Rodríguez‐Antona, C., Martínez‐Delgado, B., Delgado, M., Díez, A., Rovira, A., et al. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20283 · Cited by 75
“On the other hand, hereditary PGLs are mainly associated with germ-line mutations in the succinate dehydrogenase (SDH) subunits: SDHB, the iron sulfur protein, associated with PGL type 4; SDHD, the small integral membrane protein, with PGL type 1; and SDHC, the remaining integral protein of the complex, with PGL type…”
BackgroundMitochondria and reactive oxygen species in renal cancer
Hervouet, É., Simonnet, H., & Godinot, C. (2007) · Biochimie · doi:10.1016/j.biochi.2007.03.010 · Cited by 83
Schovánek, J., Martucci, V. L., WESLEY, R. A., Fojo, T., Rivero, J. D., Huynh, T., Adams, K. T., Kebebew, E., Fryšák, Z., Stratakis, C. A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-523 · Cited by 84
“in 2001 [3], have been linked to more aggressive tumor behavior, presenting with a higher metastatic rate than other PHEOs/PGLs [3-7].”
Succinate Dehydrogenase-deficient Tumors: Diagnostic Advances and Clinical Implications
Barletta, J. A., & Hornick, J. L. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31825c6bc6 · Cited by 79
Kytölä, S. I., Nord, B., Elder, E. E., Carling, T., Kjellman, M., Cedermark, B., Juhlin, C., Höög, A., Isola, J. J., & Larsson, C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10081 · Cited by 78
“This variant has not been detected in any of the other studies performed so far (Baysal et al., 2000; Gimm et al., 2000; Astuti et al., 2001a; Badenhop et al., 2001; Milunsky et al., 2001; Taschner et al., 2001) and in none of the 200 normal controls.”
da Silva, N. F., Gentle, D., Hesson, L. B., Morton, D. G., Latif, F., & Maher, E. R. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.11.820 · Cited by 73
Self-citationDannenberg, H., Dinjens, W. N. M., Abbou, M., van Urk, H., Pauw, B. K. H., Mouwen, D., Mooi, W. J., & de Krijger, R. R. (2002) · PubMed · Cited by 81
Huang, J., & Lemire, B. D. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.02.028 · Cited by 80
Neumann, H. P. H., Young, W. F., Krauß, T., Bayley, J., Schiavi, F., Opocher, G., Boedeker, C. C., Tirosh, A., Castinetti, F., Ruf, J., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0085 · Cited by 82
Self-citationThe Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 84
“4 and 5).”
Jafri, M., Whitworth, J., Rattenberry, E., Vialard, L., Kilby, G., Kumar, A., Izatt, L., Lalloo, F. I., Brennan, P., Cook, J. A., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12074 · Cited by 76
Self-citationRøsland, G. V., Dyrstad, S. E., Tusubira, D., Helwa, R., Tan, T. Z., Lotsberg, M. L., Pettersen, I. K. N., Berg, A., Kindt, C. K., Hoel, F., et al. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0197-8 · Cited by 72
Genetics of pheochromocytomas and paragangliomas
Opocher, G., & Schiavi, F. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.05.001 · Cited by 77
Cleven, A. H. G., Suijker, J., Agrogiannis, G., Bruijn, I. H. B., Frizzell, N., Hoekstra, A. S., Wijers‐Koster, P. M., Cleton-Jansen, A., & Bovée, J. V. M. G. (2017) · Clinical Sarcoma Research · doi:10.1186/s13569-017-0074-6 · Cited by 75
Mahdi, H., Mester, J. L., Nizialek, E. A., Ngeow, J. Y. Y., Michener, C. M., & Eng, C. (2014) · Cancer · doi:10.1002/cncr.29106 · Cited by 71
“3 (1-69) PTEN protein level, n (%) 1 69 (27.”
Self-citationGenomic imprinting and environment in hereditary paraganglioma
Baysal, B. E. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30018 · Cited by 74
“Subsequently mutations in two other complex II subunits, SDHC (PGL3) [Niemann and Muller, 2000] and SDHB (PGL4) [Astuti et al., 2001], were discovered in familial paragangliomas by direct candidate gene analyses.”
BackgroundThe Genetics of Neuroendocrine Tumors
Öberg, K. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.005 · Cited by 77
Morris, M. R., Maina, E., Morgan, N. V., Gentle, D., Astuti, D., Moch, H., Kishida, T., Yao, M., Schraml, P., Richards, F. M., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.011767 · Cited by 70
Self-citationMurakumo, Y., Jijiwa, M., Asai, N., Ichihara, M., & Takahashi, M. (2006) · Pituitary · doi:10.1007/s11102-006-0263-4 · Cited by 75
The basic science of glomus jugulare tumors
Heth, J. (2004) · Neurosurgical FOCUS · doi:10.3171/foc.2004.17.2.2 · Cited by 70
Pheochromocytoma and Paraganglioma
Pacák, K., & Wimalawansa, S. J. (2015) · Endocrine Practice · doi:10.4158/ep14481.ra · Cited by 77
Metabolic adaptations in prostate cancer
Pujana-Vaquerizo, M., Bozal‐Basterra, L., & Carracedo, A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02762-z · Cited by 98
Mutation of SDHB is a Cause of Hypoxia-Related High-Altitude Paraganglioma
Cerecer-Gil, N. Y., Figuera, L. E., Llamas, F. J., Lara, M., Escamilla, J. G., Ramos, R., Estrada, G., Hussain, A. K., Gaal, J., Korpershoek, E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0637 · Cited by 71
HIF and fumarate hydratase in renal cancer
Sudarshan, S., Linehan, W. M., & Neckers, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603547 · Cited by 71
Goffrini, P., Ercolino, T., Panizza, E., Giache, V., Cavone, L., Chiarugi, A., Dima, V., Ferrero, I., & Mannelli, M. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp102 · Cited by 69
Evolving concepts in pheochromocytoma and paraganglioma
Dahia, P. L. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198017.45982.06 · Cited by 69
Self-citationHoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate
Goncalves, J., Moog, S., Morin, A., Gentric, G., Müller, S., Morrell, A. P., Kľučková, K., Stewart, T. J., Andoniadou, C. L., Lussey‐Lepoutre, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2936 · Cited by 81
“In these studies, all SDHx- and FH-mutated tumors clustered together, showing a transcriptome signature characterized by activation of the hypoxic response pathway (2, 15, 16) and a DNA hypermethylator phenotype (17).”
BackgroundGastrointestinal stromal tumours: from KIT to succinate dehydrogenase
Doyle, L. A., & Hornick, J. L. (2013) · Histopathology · doi:10.1111/his.12302 · Cited by 72
Enzymatic features of the glucose metabolism in tumor cells
Herling, A., König, M., Bulik, S., & Holzhütter, H. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08174.x · Cited by 75
Gene Expression Profiling of Benign and Malignant Pheochromocytoma
Brouwers, F. M., Elkahloun, A. G., Munson, P. J., Eisenhofer, G., Barb, J. J., Linehan, W. M., Lenders, J. W. M., de Krijger, R. R., Mannelli, M., Udelsman, R., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.058 · Cited by 73
“The comparison of malignant primary with benign tumors (4) indicated a disproportionate number of differentially expressed genes associated with signal transduction, while the comparison of malignant primary tumors with metastases (5) indicated an importance of genes related to cell proliferation, cytoskeletal functio…”
BackgroundMethod
Metadata
- Authors
- Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R.
- Affiliations
- University of Birmingham (GB)
- Dana-Farber Cancer Institute (US)
- Royal Victoria Infirmary (GB)
- Queen Elizabeth Hospital (GB)
- Uppsala University (SE)
- University of Cambridge (GB)
- Corresponding author
- Maher, Eamonn R.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 69
- Issue
- 1
- Pages
- 49-54
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1226047
- OpenAlex
- W2025719835
- Cited by
- 1,087
- References
- 28
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 18 · 2023: 31 · 2022: 29 · 2021: 40 · 2020: 29 · 2019: 51 · 2018: 42 · 2017: 47 · 2016: 54 · 2015: 46 · 2014: 70 · 2013: 61 · 2012: 75
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4401 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- British Heart Foundation
- National Cancer Institute (P-30-CA-16058, P30CA016058)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- succinate dehydrogenase, SDHB, SDHC, pheochromocytoma, paraganglioma, germline mutations, mitochondrial dysfunction, sporadic pheochromocytoma, tumor suppressor, RET proto-oncogene, VHL, neurofibromatosis type 1
- MeSH terms
- Proto-Oncogene Mas, Amino Acid Sequence, Base Sequence, DNA Mutational Analysis, Female, Haplotypes, Humans, Male, Molecular Sequence Data, Mutation, Paraganglioma, Pedigree, Pheochromocytoma, Succinate Dehydrogenase, Sequence Alignment, Germ-Line Mutation, Loss of Heterozygosity, Genetic Predisposition to Disease, Mutation, Missense, Protein Subunits
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.